| 0.49 -0.01 (-1.9%) | 02-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.65 | 1-year : | 0.72 |
| Resists | First : | 0.55 | Second : | 0.61 |
| Pivot price | 0.54  |
|||
| Supports | First : | 0.46 | Second : | 0.38 |
| MAs | MA(5) : | 0.5 |
MA(20) : | 0.56 |
| MA(100) : | 0.66 |
MA(250) : | 0.81 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 21  |
D(3) : | 17.6 |
| RSI | RSI(14): 32.3 |
|||
| 52-week | High : | 1.4 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XRTX ] has closed above bottom band by 7.2%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.51 - 0.52 | 0.52 - 0.52 |
| Low: | 0.48 - 0.49 | 0.49 - 0.49 |
| Close: | 0.48 - 0.49 | 0.49 - 0.49 |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Fri, 30 Jan 2026
XORTX Therapeutics Inc. (XRTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Wed, 31 Dec 2025
XORTX Leans Into Genetic Breakthroughs in Gout as It Reshapes Board and Advances Oxypurinol - TipRanks
Wed, 31 Dec 2025
XORTX Announces Pioneering Research on Genome-Wide - GlobeNewswire
Wed, 31 Dec 2025
Huge gout genetics study highlights target in kidney disease research - Stock Titan
Tue, 21 Oct 2025
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering - Yahoo Finance
Mon, 20 Oct 2025
XORTX (NASDAQ: XRTX) gets $1.00 bid-price notice; 180-day window, listing intact - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 10.1 (%) |
| Held by Institutions | 4 (%) |
| Shares Short | 64 (K) |
| Shares Short P.Month | 36 (K) |
| EPS | -0.41 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -45.4 % |
| Return on Equity (ttm) | -94.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.36 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -1.2 |
| PEG Ratio | 0 |
| Price to Book value | 1.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|